Abbott India Ltd. (ABBOTINDIA) fundamentals
Abbott India Ltd. is a listed company in Pharmaceuticals & Biotechnology, part of the Healthcare sector, listed on the NSE as ABBOTINDIA (ISIN INE358A01014). This page carries its reported financials, balance sheet, cash flow, shareholding pattern and valuation ratios.
What Abbott India Ltd. does
Abbott India Limited is an India-based pharmaceutical company. The Company is involved in product development, manufacturing, sales, and customer service. It distributes products and solutions in multiple therapeutic categories, such as women's health, gastroenterology, cardiology, metabolic disorders and primary care. It operates in a single reportable business segment, which is Pharmaceuticals. The Company’s products include Arachitol Nano, Digeraft, Influvac, Colospa, Duphalac, Librax, Creon, Duphaston, Prothiaden, Cremaffin, Duvadilan, Thyronorm, Cremaffin Plus, Ganaton, Udiliv, Digene, Heptral, Vertin, Zolfresh, Citrosoda UTI, Digene Insta On The Go, Digeraft tablet, Duphaston OD, Pneumoshield 14, Prothiaden Neu, Vonefi, Levesam, and LOBATE M Skin Cream, among others. The Company sells its products through independent distributors primarily within India.
Valuation and market data
| Last close | ₹25550.00 |
|---|---|
| Market capitalisation | ₹54,294 crore |
| Enterprise value | ₹54,103 crore |
| P/E (TTM) | 34.98 |
| Price to book | 11.37 |
| Price to sales (TTM) | 4.36 |
| Book value per share | ₹2246.68 |
| Dividend yield | 256.75% |
| Sector | Healthcare |
| Industry | Pharmaceuticals & Biotechnology |
| Listed since | Fri Jan 08 |
Annual results
| Period | Revenue | Profit before tax | Net profit | EPS |
|---|---|---|---|---|
| Mar 2026 | ₹7,217 crore | ₹2,079 crore | ₹1,552 crore | 730.36 |
| Mar 2025 | ₹6,685 crore | ₹1,887 crore | ₹1,414 crore | 665.62 |
| Mar 2024 | ₹6,097 crore | ₹1,618 crore | ₹1,201 crore | 565.28 |
| Mar 2023 | ₹5,503 crore | ₹1,274 crore | ₹949 crore | 446.80 |
| Mar 2022 | ₹4,996 crore | ₹1,080 crore | ₹799 crore | 375.87 |
Figures are as reported (standalone), in ₹ crore.
Shareholding pattern
As of Jun 2026:
| Promoters | 75.0% |
|---|---|
| Foreign institutions (FII) | 0.4% |
| Mutual funds | 7.4% |
| Other domestic institutions | 1.3% |
| Retail and others | 15.8% |
More on BreakPoint
FundaX company research covers every listed company with reported financials. BreakPoint Pro adds the BreakPoint iQ score, the screener and the multibagger board.
Data is sourced from exchange filings and vendor feeds and is for research, not investment advice. Figures can be restated by the company after publication.